Article

Drug target Mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases prevention

2023-11-05

Abstract excerpt

<h4>Background and aims</h4> Inhibitors of apolipoprotein C-III (apoC3) are currently approved for the reduction of triglyceride levels in patients with Familial Chylomicronemia Syndrome. We used drug target Mendelian randomization (MR) to assess the effect of genetically predicted decrease in APOC3 blood protein levels on cardiometabolic traits and diseases. <h4>Methods</h4> We quantified lifelong reductions in A...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2c486d81-feed-52f7-8b57-3a3ba148cbd6
DOI: 10.1101/2023.11.04.23298088

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Drug target Mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases preventionDOI 10.1101/2023.11.04.23298088Read

Drug target Mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases prevention.Semantic proximity Read

Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease riskSemantic proximity Read

Joint Associations of APOC3 and LDL-C-Lowering Variants With the Risk of Coronary Heart Disease.Semantic proximity Read

LDL-C and TC Mediate the Risk of PNPLA3 Inhibition in Cardiovascular DiseasesSemantic proximity Read

Genetic inhibition of angiopoietin-like protein-3, lipoprotein-lipid levels and cardiometabolic diseasesSemantic proximity Read

Metabolomic signatures of lipid-modifying therapies using drug target Mendelian randomizationSemantic proximity Read

Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic riskSemantic proximity Read

Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisationSemantic proximity Read

Evaluating genetically-predicted causal effects of lipoprotein(a) in human diseases: a phenome-wide Mendelian randomization studySemantic proximity Read

Association of genetically predicted lipid traits and lipid-modifying targets with heart failureSemantic proximity Read